RxDoctor Payments Data

Rolando Rivera, MD

Urology · Naples, FLNPI 1295786093

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $278,928 of the $436,670 with a category attached, or 63.9%. Teleflex LLC accounts for 71.1% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2023 at $131,291 and has fallen 78.1% since, to $28,727 in 2025. Among urology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$436,670in general payments, 2019–2025

Across 1,176 payments — averaging $371.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$310K
  • Neotract Inc.$67K
  • Axonics, Inc.$12K
  • Intuitive Surgical$11K
  • Valencia Technologies Corporation$8K
  • Sumitomo Pharma America, Inc.$3K
  • plus $25K from 54 others

What the payments were for

  • Consulting fees$78,77418%
  • Speaking & faculty fees$278,92864%
  • Travel & lodging$31,8817%
  • Food & beverage$35,6508%
  • Education$11,3653%
  • Gifts$720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teleflex LLC380$310,452
Neotract Inc.109$66,941
Axonics, Inc.95$12,017
Intuitive Surgical11$10,926
Valencia Technologies Corporation8$7,883
Sumitomo Pharma America, Inc.29$3,174
Bayer25$3,091
Boston Scientific45$2,586
Astellas Pharma US Inc63$2,306
Urovant Sciences Inc4$1,686
Dendreon Pharmaceuticals LLC43$1,531
Procept Biorobotics Corporation14$1,427
Uromedica, Incorporated1$1,000
Coloplast27$894
Johnson & Johnson34$880
Medtronic(2 entities)11$725
AbbVie(2 entities)29$696
Ferring Pharmaceuticals Inc.20$682
Endo Pharmaceuticals Inc.25$600
SRS Medical Systems, Inc.6$571
AstraZeneca11$537
Pfizer22$417
Ambu Inc.7$368
Urogen Pharma, Inc.10$344
Merck16$338
Blue Earth Diagnostics13$320
Photocure Inc3$310
Olympus America Inc.5$295
Baudax Bio Inc.3$254
Novartis9$210
Myriad Genetic Laboratories, Inc.6$209
Bioprotect Medical, Inc.4$204
Palette Life Sciences, Inc.2$187
Laborie Medical Technologies Corp.5$169
Myovant Sciences Inc.9$162
Endo USA, Inc.6$156
Telix Pharmaceuticals3$152
Antares Pharma, Inc.8$149
Tolmar Pharmaceuticals, Inc.7$149
Calyxo, Inc.1$148
Baxter Healthcare1$145
Tolmar, Inc.6$135
Novo Nordisk1$111
Femselect Inc.1$110
Amgen8$108
Bluewind Medical2$106
Caldera Medical, Inc1$104
Sun Pharmaceutical Industries Inc.4$94
Rochester Medical Corporation1$80
Urogpo LLC1$70
Accord Healthcare, Inc.3$66
C. R. Bard, Inc. & Subsidiaries1$62
Progenics Pharmaceuticals, Inc.2$50
Alnylam Pharmaceuticals Inc.2$42
Dentsply IH Inc.2$31
Acerus Pharmaceuticals Corporation1$27
Civco Medical Instruments1$25
Innovation Technologies Inc1$24
Immunitybio, Inc.1$23
BD1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$436,670 in reported general payments places this provider in the 95th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$595,452
Medicare patients
1,386
Services billed
10,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide58$820,908
ErleadaApalutamide36$463,076
OrgovyxRelugolix74$199,942
MyrbetriqMirabegron222$182,134
GemtesaVibegron68$75,905
Abiraterone Acetate18$23,820
Testosterone42$7,124
Silodosin86$6,868
Mirabegron ErMirabegron16$6,629
Testosterone Cypionate74$4,415
Dutasteride96$4,345
Cephalexin139$3,740
Tamsulosin Hcl234$3,725
Alfuzosin Hcl ErAlfuzosin Hcl96$2,300
Estradiol38$2,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$2,306$1,003,042280 claims
Johnson & JohnsonErleada$880$463,07636 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$3,174$275,847142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 935 urology providers in Florida.

Other urology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →